Establishment of a DBS for the procurement of drugs from the antibiotics indication group in various dosage forms.

The DBS takes place in 2 phases:

1. Establishment and administration of a pool of bidders

The DBS is set up for the duration specified in Section 1.2 and for the range of antibiotics. The procedure is carried out electronically only. The contracting authority forms a pool of bidders.

Anyone interested can activate participation in the procedure at any time during the DBS and submit an application to participate. Any interested party who meets the eligibility criteria published in the notice will be included in the bidder pool. He thus becomes a potential bidder and can submit an offer for the subsequent individual awards.

The pool of bidders is not limited in size. Every qualified participant is included in the bidder pool.

2. Offer phase

The specific procurements take place depending on the needs of the public client in the context of the offer phase in the form of individual awards. The client decides on the point in time or the number of individual awards. It is expressly pointed out that there is no obligation on the part of the client to carry out individual awards.

On the occasion of the individual award, the contracting authority requests all participants in the pool of bidders who are approved for the DBS to submit an offer and informs them of the specific conditions of the contract (e.g. quantity, delivery time, place of delivery, award criteria, etc.), unless these are already the notice were published.

By submitting an offer, the bidder declares that there will be no changes to the suitability criteria. The offers received will be checked in terms of content and against the announced award criteria. The bidder with the most economical offer to be determined on the basis of the notified award criteria will be awarded the contract.

The participants admitted to the DBS bidder pool are not obliged to submit an offer as part of the individual awards.

The participants must always find out about the current status of the award procedure (the individual award). Any deadline extensions, applicant questions with the corresponding answers or other updates and changes must be accessed independently by the participant on the federal e-procurement platform. Any changes will be announced immediately by the client.

The DBS intends to contract a total of approximately 29,000,000 units, for example of the following active ingredients from the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants.

The specified quantities (total requirement = duration of the DBS; requirement 2021 = expected annual requirement 2021) represent forecast values.

It is expressly pointed out that further active ingredients can be placed through individual awards.

Legend: AMP = ampoule, EA = piece, TU = tube, BT = bottle, PR = pair, IE = international unit

Antidota:

"1. Atropine sulfate injection (active ingredient ATROPIN 0.5 MG / ML), total requirement approx. 91 800 AMP, requirement 2021 approx. 48 500 AMP,

2. Dimercaptopropane sulfonic acid (active ingredient dimercaptopropane sulfonic acid 10 MG), total requirement approx. 50,000 EA, requirement 2021 0 EA,

3. Flumazenil injection (active ingredient flumazenil 0.5 MG / 5ML), total requirement approx. 33,000 AMP, requirement 2021 approx. 21,400 AMP,

4. Naloxone hydrochloride injection (active ingredient naloxone 0.4 MG / ML), total requirement approx. 87 400 AMP, requirement 2021 approx. 65 200 AMP.

Corticoids:

1. Prednisolone sodium succinate for injection (active ingredient Prednisolone 250 MG), total requirement approx. 110 200 PR, requirement 2021 approx. 85 300 PR,

2. Prednisolone tablet (active ingredient prednisolone 5 MG, divisible), total requirement approx. 246 500 EA, requirement 2021 0 EA,

3. Prednisolone tablet (active ingredient Prednisolone 50 MG, quarterable), total requirement approx. 152,000 EA, requirement 2021 approx. 120 EA,

4. Prednisone tablet (active ingredient prednisone 20 MG), total requirement approx. 144 200 EA, requirement approx. 7 200 EA in 2021. "

The DBS intends to contract a total of approximately 29,000,000 units, for example of the following active ingredients from the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants.

The specified quantities (total requirement = duration of the DBS; requirement 2021 = expected annual requirement 2021) represent forecast values.

It is expressly pointed out that further active ingredients can be placed through individual awards.

Legend: AMP = ampoule, EA = piece, TU = tube, BT = bottle, PR = pair, IE = international unit

Narcotics:

"1. Bupivacaine with epinephrine (active ingredient 1 bupivacaine hydrochloride 0.5% / ML, active ingredient 2 epinephrine hydrogen tartrate 0.0005%), total requirement approx. 199 700 AMP, requirement 2021 approx. 97 900 AMP,

2. Butylscopolaminium bromide tablet (active ingredient Butylscopolaminiumbromid 10 MG / TBL), total requirement approx. 1 324 800 EA, requirement 2021 approx. 106 800 EA,

3. Lorazepam Plaettchen (active ingredient Lorazepam 1 MG / SMT), total requirement approx. 328 800 EA, requirement 2021 approx. 195 600 EA,

4.Midazolam hydrochloride injection (active ingredient MIDAZOLAM 5 MG / 5ML), total requirement approx. 105 100 AMP, requirement 2021 approx. 65 900 AMP,

5. Propofol injection (active ingredient Propofol 10 MG / ML), total requirement approx. 101 800 AMP, requirement 2021 approx. 32 400 AMP. "

The DBS intends to contract a total of approximately 29,000,000 units, for example of the following active ingredients from the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants.

The specified quantities (total requirement = duration of the DBS; requirement 2021 = expected annual requirement 2021) represent forecast values.

It is expressly pointed out that further active ingredients can be placed through individual awards.

Legend: AMP = ampoule, EA = piece, TU = tube, BT = bottle, PR = pair, IE = international unit

Analgesics:

"1. Acetylsalicylic acid tablets (active ingredient acetylsalicylic acid 500 MG / TBL), total requirement approx. 294 200 EA, requirement 2021 approx. 48 300 EA,

2. Dexketoprofentrometamol tablets (active ingredient dexketoprofen 25 MG / TBL), total requirement approx. 378 300 EA, requirement 2021 0 EA,

3. Diclofenac diethylamine gel (active ingredient diclofenac 9.31 MG / 1G), total requirement approx. 148 800 TU, requirement 2021 approx. 4 900 TU,

4. Diclofenac sodium capsules (active ingredient Diclofenac 69.82 MG / KPS), total requirement approx. 986 800 EA, requirement 2021 0 EA,

5. Diclofenac sodium effervescent tablet (active ingredient diclofenac 46.50 MG / BTBL), total requirement approx. 905 400 EA, requirement 2021 0 EA,

6. Ibuprofen tablets (active ingredient ibuprofen 400 MG / TBL, divisible), total requirement approx. 16 203 500 EA, requirement 2021 approx. 332 800 EA,

7. Sodium metamizole injection (active ingredient metamizole 2215.41 MG / 5ML), total requirement approx. 63 900 AMP, requirement 2021 approx. 58 900 AMP,

8. Paracetamol tablet (active ingredient paracetamol 500 MG / TBL), total requirement approx. 1 854 000 EA, requirement approx. 290 300 EA in 2021. "

The DBS intends to contract a total of approximately 29,000,000 units, for example of the following active ingredients from the indication groups antidotes, corticoids, narcotics, analgesics and anticoagulants.

The specified quantities (total requirement = duration of the DBS; requirement 2021 = expected annual requirement 2021) represent forecast values.

It is expressly pointed out that further active ingredients can be placed through individual awards.

Legend: AMP = ampoule, EA = piece, TU = tube, BT = bottle, PR = pair, IE = international unit

Anticoagulants:

"1. Acetylsalicylic acid tablet, DAB (active ingredient acetylsalicylic acid 100 MG), total requirement approx. 536,500 EA, requirement 2021 approx. 6,000 EA,

2. Enoxaparin sodium injection (active ingredient enoxaparin sodium 40 MG), total requirement approx. 309 600 EA, requirement 2021 approx. 44 800 EA,

3. Heparin sodium injection (active ingredient heparin sodium 25000 IU), total requirement approx. 95 400 BT, requirement 2021 approx. 70 500 BT,

4. Rivaroxaban tablets (active ingredient rivaroxaban 20 MG), total requirement approx. 90,300 EA, requirement approx. 2,400 EA in 2021. "